Search

• GSK completes major three-part transaction with Novartis

  Media

  GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion

  https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/

  First published: 02 March 2015

• GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)

  Media

  GSK announced that the EC has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide).

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-authorisation-for-once-weekly-type-2-diabetes-treatment-eperzan-albiglutide/

  First published: 26 March 2014

• GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma

  Media

  GSK announced that the FDA has granted Priority Review designation to the use of Tafinlar® & Mekinist® for the treatment of melanoma

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-priority-review-from-fda-for-dabrafenibtrametinib-combination-in-metastatic-melanoma/

  First published: 16 September 2013

• Japan’s Ministry of Health, Labour and Welfare accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older

  Media

  Shingrix was initially approved in 2018 by the Japanese MHLW to prevent shingles in adults aged 50 years or older

  https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older/

  First published: 28 June 2022

• GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer

  Media

  The PERLA phase II trial is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-perla-the-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-in-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer/

  First published: 05 October 2022

• Data published on Anoro® Ellipta® demonstrate improved lung function compared to tiotropium

  Media

  Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro® Ellipta®.

  https://www.gsk.com/en-gb/media/press-releases/data-published-on-anoro-ellipta-demonstrate-improved-lung-function-compared-to-tiotropium/

  First published: 17 October 2014

• GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma

  Media

  GSK and THRX announced the submission of a new drug application for asthma in patients aged 12 years and older, brand name Breo® Ellipta®.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-submission-to-us-regulatory-authorities-for-fluticasone-furoatevilanterol-in-asthma/

  First published: 30 June 2014

• GSK announces changes to its global sales and marketing practices to further ensure patient interests come first

  Media

  GSK today set out plans to evolve the way it sells and markets its products to healthcare professionals.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-its-global-sales-and-marketing-practices-to-further-ensure-patient-interests-come-first/

  First published: 17 December 2013

• Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

  Media

  ViiV announced the FDA has approved Juluca®, complete regimen for the maintenance treatment of HIV-1 infection in virologically suppressed..

  https://www.gsk.com/en-gb/media/press-releases/juluca-approved-in-us-as-first-2-drug-regimen-once-daily-single-pill/

  First published: 21 November 2017

• ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe

  Media

  ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/

  First published: 23 March 2018